The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.
How this was made
The 30-second read
Why it matters
These disclosures introduce new therapeutic candidates and the first FDA approval for a chronic hepatitis B antisense drug, reshaping the competitive landscape.
Market read
First‑report trial data and a new FDA approval provide fresh catalysts for several biotech stocks, with potential short‑term price moves.
What to watch
Potential reimbursement challenges and competition from existing HBV/HDV therapies could limit upside.
Background
The Liver Meeting 2026 presented multiple late‑breaking trial results across hepatitis‑D, hepatitis B functional cure, and metabolic‑associated steatohepatitis (MASH).
Ticker impact
FDA approved bepirovirsen (Hibsago) for chronic hepatitis B, first antisense therapy.
likely upward pressure as market prices in new product launch
First FDA approval for a novel HBV therapy, with pricing to be set soon.
Gilead's bulevirtide (Hepcludex) referenced as comparator in HDV trials.
potential downside as market anticipates future competition
Trial data suggest alternative therapies may erode bulevirtide market share.
Gilead Sciences' bulevirtide mentioned as head‑to‑head comparator in upcoming ECLIPSE 3 trial.
short‑term volatility, direction dependent on trial outcome
Market awaits comparative efficacy results.
Merck's glucagon‑like peptide‑1/glucagon co‑agonist efinopegdutide showed MASH resolution in phase 2b.
upward bias as investors price in potential new indication
Phase 2b results with statistically significant improvement over placebo.
Novo Nordisk's semaglutide used as reference arm in the efinopegdutide MASH trial.
stable to modestly positive as trial validates existing therapy
Semaglutide performed comparably, reinforcing its therapeutic value.
Market effects
Biotech sector may see heightened interest in hepatitis‑D and metabolic‑liver therapies.
US and European biotech stocks could experience short‑term moves tied to trial outcomes.
Global investors tracking FDA approvals and late‑stage liver‑disease pipelines.
Counterpoint
Skeptics may argue that early‑stage data do not guarantee commercial success, especially given pricing uncertainties.
Key entities
- companyVir Biotechnology
Developer of elebsiran + tobevibart HDV regimen.
- companyMirum Pharmaceuticals
Developer of brelovitug HDV antibody.
- companyGSK
Approved bepirovirsen for chronic hepatitis B.
- companyMerck
Developer of efinopegdutide for MASH.
